BioSpace News Archive

Fluidx Medical’s GPX Embolic Device was used to effectively devascularize a large tumor with multiple feeding vessels as part of a multi-center clinical trial.

4D pharma plc today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously disclosed positive topline results from Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma.

Zealand Pharma A/S today announced completion of patient enrollment in its pivotal Phase 3 trial (EASE-SBS 1) of glepaglutide, the company’s long-acting GLP-2 analog, for the potential treatment of short bowel syndrome (SBS).

Brooklyn ImmunoTherapeutics, Inc. today announces the appointment of two new members of the Company’s Board of Directors.

As reported in the Lancet Neurology, daridorexant is the first insomnia medication to demonstrate an effect of a drug therapy to improve both nighttime symptoms and daytime functioning.

Chimerix announced Mike Andriole, Chief Business and Financial Officer, will present a corporate overview at the B. Riley Virtual Oncology Conference on Thursday, January 27, 2022 at 3:00 p.m. ET.

CytomX Therapeutics, Inc., a leader in the field of conditionally activated therapeutics, announced that on January 18, 2022, the Company granted four new employees options to purchase a total of 127,000 shares of the Company’s common stock at an exercise price per share equal to $3.83, which was the closing trading price on January 18, 2022, the date of the grant.

F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the United States Patent and Trademark Office (USPTO) has granted a patent protecting the composition of matter of FS118, F-star’s tetravalent bispecific antibody which blocks PD-L1 and LAG-3 receptors.

BioVie Inc. today announced the treatment of the first patient in the Company’s Phase 2 clinical trial assessing the potential pro-motoric impact of its NE3107 asset in Parkinson’s disease patients.

Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan.